Human Papillomavirus Type 11 Inhibitors(Boehringer Ingelheim Ltd)(Human Papillomavirus Type 11 Inhibitors(Boehringer Ingelheim Ltd))

概要

基本信息

药物类型

小分子化药

别名

HPV-11 E1-E2 inhibitors、human papillomavirus type 11 inhibitors(Boehringer Ingelheim Ltd)

靶点

HPV E1 x HPV E2

作用机制

HPV E1抑制剂(HPV病毒E1蛋白抑制剂)、HPV E2抑制剂(HPV病毒E2蛋白抑制剂)

治疗领域

感染

在研适应症-

非在研适应症

乳头状瘤病毒感染

原研机构

Boehringer Ingelheim GmbH

在研机构-

非在研机构

Boehringer Ingelheim GmbH

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Human Papillomavirus Type 11 Inhibitors(Boehringer Ingelheim Ltd) 相关的临床结果

登录后查看更多信息

100 项与 Human Papillomavirus Type 11 Inhibitors(Boehringer Ingelheim Ltd) 相关的转化医学

登录后查看更多信息

100 项与 Human Papillomavirus Type 11 Inhibitors(Boehringer Ingelheim Ltd) 相关的专利（医药）

登录后查看更多信息

1

项与 Human Papillomavirus Type 11 Inhibitors(Boehringer Ingelheim Ltd) 相关的文献（医药）

1998-07-01·Journal of Virology2区 · 医学

Human Papillomavirus Type 11 Recombinant L1 Capsomeres Induce Virus-Neutralizing Antibodies

2区 · 医学

Article

作者: Garcea, Robert L. ; White, Wendy I. ; Rose, Robert C. ; Lane, Christopher ; Suzich, JoAnn A. ; Li, Maolin

ABSTRACT The human papillomavirus type 11 (HPV-11) L1 major capsid protein can be trypsinized to generate recombinant capsomeres that retain HPV genotype-restricted capsid antigenicity (M. Li, T. P. Cripe, P. A. Estes, M. K. Lyon, R. C. Rose, and R. L. Garcea, J. Virol. 71:2988–2995, 1997). In the present study, HPV-11 virion-neutralizing monoclonal antibodies H11.F1 and H11.H3, previously characterized as recognizing two distinct HPV-11 capsid-neutralizing antigenic domains (S. W. Ludmerer, D. Benincasa, and G. E. Mark III, J. Virol. 70:4791–4794, 1996), were each found to be highly immunoreactive with trypsin-generated capsomeres in an enzyme-linked immunosorbent assay (ELISA). Capsomeres were used to generate high-titer polyclonal immune sera that demonstrated HPV genotype-restricted reactivity by ELISA. The capsomere antisera were then tested in an in vitro infectivity assay and found to neutralize HPV-11 virions. In this assay, HPV-11 capsomere polyclonal antisera exhibited neutralization titers (10 −5 to 10 −6 ) comparable to those obtained with a virion-neutralizing antiserum raised previously against intact HPV-11 VLPs (R. C. Rose, R. C. Reichman, and W. Bonnez, J. Gen. Virol. 75:2075–2079, 1994). These results indicate that highly immunogenic, genotype-restricted HPV capsid-neutralizing antigenic domains are contained entirely within capsomeres. Thus, capsomeres may be viable vaccine candidates for the prevention of HPV disease.

100 项与 Human Papillomavirus Type 11 Inhibitors(Boehringer Ingelheim Ltd) 相关的药物交易

登录后查看更多信息